Norwood Abbey specialises in developing and commercialising innovative projects and technologies that address significant unmet needs in the medical industry.

Norwood is developing its technologies in collaboration with pre-eminent Australian and international clinical research institutions and commercial partners. Together Norwood and its partners are applying the technology platforms to address some of today's most challenging and complex clinical problems.

Norwood’s strategy is to establish key strategic alliances and partnerships with the objective of improving people's lives.

 

Norwood Abbey .........................

"Partnerships to Improve People's Lives"

5/26/2009 - NAL and NIM Half Yearly Reports



4/30/2009 - Appendix 4C - quarterly



4/20/2009 - Norwood Immunology Virosome Sale and Dividend



4/20/2009 - NIM Virosome deal completed & general update



3/16/2009 - Norwood Abbey Update



2/13/2009 - FURTHER CHINESE NEEDLEFREE PATENT GRANTED



12/15/2008 - NAL closes additional fundraising



10/27/2008 - Further Micro-Needle Patent Granted in USA



10/20/2008 - 2008 Annual Report



9/26/2008 - NIM Stem Cell Developments



9/22/2008 - Russian Federation Eyecare Patent



7/17/2008 - Medimmune: Exclusive agreement with Virosome



5/21/2008 - US Microneedle Patent granted



5/3/2007 - Microneedle Patent Granted



4/17/2007 - Needle-Free Injection - Vaccine Breakthrough



4/4/2007 - Needle-Free Controlled Depth Video